Drug Approval | November 24, 2023
Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
This product will be manufactured at Lupin’s Pithampur facility in India
The new logo incorporates three beating hearts seamlessly & reinforces 'healthcare with a heart' into the Group's visual identity
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Tadalafil Tablets USP, 20 mg had annual sales of USD 61 mn in the United States (IQVIA MAT April 2023)
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
The company had acquired 26,000 equity shares having face value of Rs. 10 each fully paid up of Eqova
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
